Astellas Bows Out Of The CVT Sweepstakes, But What’s Next?
This article was originally published in PharmAsia News
Executive Summary
Usually, having more money that you know how to use is not considered a problem, but cash-rich Astellas may feel a bit stranded now that Gilead has trumped its bid to buy CV Therapeutics. But at least one analyst thinks the U.S. biotech sector still offers plenty of potential acquisitions for the Japanese pharma